195 related articles for article (PubMed ID: 25641511)
1. Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.
Coe LM; Tekalur SA; Shu Y; Baumann MJ; McCabe LR
J Cell Physiol; 2015 Aug; 230(8):1944-53. PubMed ID: 25641511
[TBL] [Abstract][Full Text] [Related]
2. Caspase-2 deficiency protects mice from diabetes-induced marrow adiposity.
Coe LM; Lippner D; Perez GI; McCabe LR
J Cell Biochem; 2011 Sep; 112(9):2403-11. PubMed ID: 21538476
[TBL] [Abstract][Full Text] [Related]
3. CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption.
Motyl KJ; Raetz M; Tekalur SA; Schwartz RC; McCabe LR
Am J Physiol Regul Integr Comp Physiol; 2011 May; 300(5):R1250-60. PubMed ID: 21346244
[TBL] [Abstract][Full Text] [Related]
4. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
5. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death.
Coe LM; Irwin R; Lippner D; McCabe LR
J Cell Physiol; 2011 Feb; 226(2):477-83. PubMed ID: 20677222
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss.
Botolin S; McCabe LR
J Cell Physiol; 2006 Dec; 209(3):967-76. PubMed ID: 16972249
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival.
Motyl KJ; McCauley LK; McCabe LR
J Cell Physiol; 2012 Apr; 227(4):1326-34. PubMed ID: 21604269
[TBL] [Abstract][Full Text] [Related]
8. Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis.
Patntirapong S; Singhatanadgit W; Arphavasin S
J Clin Pharm Ther; 2014 Aug; 39(4):349-53. PubMed ID: 24661151
[TBL] [Abstract][Full Text] [Related]
9. Low dose aspirin therapy decreases blood glucose levels but does not prevent type i diabetes-induced bone loss.
Coe LM; Denison JD; McCabe LR
Cell Physiol Biochem; 2011; 28(5):923-32. PubMed ID: 22178944
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate Withdrawal: Effects on Bone Formation and Bone Resorption in Maturing Male Mice.
Ko FC; Karim L; Brooks DJ; Bouxsein ML; Demay MB
J Bone Miner Res; 2017 Apr; 32(4):814-820. PubMed ID: 27925290
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
12. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.
Weinstein RS; Chen JR; Powers CC; Stewart SA; Landes RD; Bellido T; Jilka RL; Parfitt AM; Manolagas SC
J Clin Invest; 2002 Apr; 109(8):1041-8. PubMed ID: 11956241
[TBL] [Abstract][Full Text] [Related]
13. Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice.
Alles N; Soysa NS; Hayashi J; Khan M; Shimoda A; Shimokawa H; Ritzeler O; Akiyoshi K; Aoki K; Ohya K
Endocrinology; 2010 Oct; 151(10):4626-34. PubMed ID: 20810563
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation.
Idris AI; Greig IR; Bassonga-Landao E; Ralston SH; van 't Hof RJ
Endocrinology; 2009 Jan; 150(1):5-13. PubMed ID: 18772231
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
16. Low bone turnover and reduced angiogenesis in streptozotocin-induced osteoporotic mice.
Peng J; Hui K; Hao C; Peng Z; Gao QX; Jin Q; Lei G; Min J; Qi Z; Bo C; Dong QN; Bing ZH; Jia XY; Fu DL
Connect Tissue Res; 2016 Jul; 57(4):277-89. PubMed ID: 27028715
[TBL] [Abstract][Full Text] [Related]
17. Alendronate enhances osseointegration in a murine implant model.
Vertesich K; Sosa BR; Niu Y; Ji G; Suhardi V; Turajane K; Mun S; Xu R; Windhager R; Park-Min KH; Greenblatt MB; Bostrom MP; Yang X
J Orthop Res; 2021 Apr; 39(4):719-726. PubMed ID: 32915488
[TBL] [Abstract][Full Text] [Related]
18. Bone inflammation and altered gene expression with type I diabetes early onset.
Motyl KJ; Botolin S; Irwin R; Appledorn DM; Kadakia T; Amalfitano A; Schwartz RC; McCabe LR
J Cell Physiol; 2009 Mar; 218(3):575-83. PubMed ID: 19006181
[TBL] [Abstract][Full Text] [Related]
19. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
[TBL] [Abstract][Full Text] [Related]
20. Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes.
Iyer S; Han L; Ambrogini E; Yavropoulou M; Fowlkes J; Manolagas SC; Almeida M
J Bone Miner Res; 2017 Jan; 32(1):60-69. PubMed ID: 27491024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
